联康生物科技集团年报2023

AGILEAGILE 目錄24712303349697576787981159160 聯康致力透過創新療程 改善患者的生活質素 我們對質量的承諾 0690 GMP– GLP-11-34Uni-PTH •GLP–1•Uni-PTHNMPAS20240004 主要財務摘要 6365789 1EBITDA (LBITDA) 2 3 4365 5365 7.3%研發費用佔收益的比例 484,718收益（千港元） 心創造新醫藥 主席報告 主席報告 主席報告 209.4484.72.31 1. 2.® 3.Skbrella ™ FN 4. ®®Ypsomed®® ®®——(BFS) Skbrella ™ FNSkbrella™ FN 促進增長國際視野 管理層討論及分析 管理層討論及分析 — ®®®® COVID-19 484.710.1%70.984.04% ® ® ®®®®®® ®Ypsomed ®® 管理層討論及分析 Skbrella ™ FN Skbrella ™ FNSkbrella™ FN Skbrella ™ FNSkbrella ™ FNSkbrella ™ FN 管理層討論及分析 UNI-PTH Uni-PTH1–34Uni-PTHUni-PTHUni-PTHUni-PTH ®Uni-PTH®Uni-PTH Uni-GLP–1 GLP–1GLP–1GLP–1Uni-GLP–1 GLP–1(DIO)DIOGLP–1GLP–1RAGLP–1 Uni-GLP–1Uni-GLP–1 ™ UB101 UB102(wAMD)UB101UB102UB102— AVEGF-A–2(Ang2) FaricimabAMD(DMO)Ang-2VEGF-AUB102Faricimab34UB102 3.44.04.8 — UB104——Fortune Business Insights240.16.1%55.2136.225.3%11.1%234.5 管理層討論及分析 Skbrella ™ FN Skbrella ™ FN1+3+2116163AlfaBODY AIHD3.03Skbrella ™ FN2Skbrella™ FNSkbrella ™ FNEGFSkbrella ™ FN DNA 25%35%211% 30–100(MSC) 管理層討論及分析 P2Y2 BFSAPI ®BFS 484.710.1% 105.412.8%91.9392.8334.917.3%4.981.0%57.8%13.6CMO9.8%10.7%48.0%49.8%®0.6%35.6 70.984.04%1.1182% ® ®®186.09.8%®261 ® 管理層討論及分析 ® ®®38.441.37.6%®164® ® ®15.0%215.1247.4 ® ®®17.410.440.2% 484.710.1% ®®226.99.2%46.8% ®®257.910.9% 392.8334.917.3%76.1%4.981.0% 211.3241.348.0%49.8%®Skbrella ™ FN® 35.635.80.6%Uni-PTH16.3718.169.8% 47.447.00.7%9.8%10.7% 13.68.657.8%CMO 管理層討論及分析 38.570.984.04%CMO 1,22417.5% ® ®®Ypsomed® 1,3201,630®® ®® 42028.4% Skbrella ™ FN Skbrella ™ FN Skbrella ™ FNSkbrella ™ FNSkbrella ™ FN ® 管理層討論及分析 EGF EGFEGF EGF EGF (RLS)(CLS) EGFEGF 129,236,000409,992,000292,471,000238,096,000200,341,000114,790,00090,255,00028.0%30.9% 17.419.1 4073119411394 管理層討論及分析 C1 C3 (1)7.1524(2)2.3524 1414A 1214A.810.1%5%14A Zethanel Properties LimitedBBBB B BBBB 董事及高級管理層簡介 37(Imperial College London)INSEAD (Capital Magazine)2020 5420 63(University of Hartford)20 Sun New Media Group Limited 49(CPA) 20 5828 68 2710CIGNA CorporationGallup Inc.Carta Group Limited 44(CFA) 18155003788 董事及高級管理層簡介 4218A(600535.SH)MBA 60GMPGLP30 4510CTANDA20 4318 44817 4116 企業管治報告 C1 C1 企業管治報告 ABC 14 企業管治報告 C.2.1 (1) (1)(2)(3) 3.21 ——————————— 企業管治報告 2/22/22/2 ————————17 17 14 1,000,0001,000,0011,500,0001,500,0012,000,0002,000,0012,500,0002,500,0013,000,0003,000,0013,500,000 企業管治報告 ——————— http://www.uni-bioscience.com 3.13 (1)(2)(3)(4) (1)(2)(3)(4)(5) 企業管治報告 C3 • • •• ••• 企業管治報告 1.6 10% 10010097100 1.2.3.133.4.5. 企業管治報告 205502 58205502(2) 223 (www.hkex.com.hk)(http://www.uni-bioscience.com) 205502info@uni-bioscience.com 企業管治報告 董事會報告 386 75 29 7831 (i)(ii) 79B22 董事會報告 40 87(1)87(2) 3.13 (1) (2)50,0001215,000,00012 董事會報告 14 36 571352C3XV 董事會報告 1.L2.(i)Automatic Result LimitedAutomatic Result1,650,971,464AutomaticResultMJKPC Holdings LimitedMJKPCHoldings Limited(ii) 29,199,0003.6,420,0004.(i)171,094,438(ii)10,480,0005.(i)8,055,000(ii)86,680,0006.7.8.9.6,364,768,147 XV 336 1.L2.Automatic Result LimitedMJKPC Holdings LimitedMJKPC Holdings Limited3.Overseas Capital Assets LimitedOverseas Capital Assets LimitedHe Rufeng4.6,364,768,147 336 董事會報告 37.8%32.6%14.5%11.7% 74.3%78.7%59.4%20.9% 5% (i)(ii) 10% 1% 1.00 (i)(ii)(iii) 董事會報告 (i)(ii)(iii)(iv)(v)(vi)(vii)(viii) 28110 202,160,0003.18%202,160,0003.18%121% (1) (2) (i)(ii)(iii)12211102 10%504,037,0127.92%143,142,012360,895,0005.67%121% 563,055,0008.85% 董事會報告 36 (1)(2)AAA(3)ABCABCABCABCABCABC40,000,000(4)DDD(5)EEEEE 37 董事會報告 16 Top Environmentally Friendly Enterprise 5R —(Reduce)—(Re-evaluate)—(Reuse)—(Recycle)—(Rescue) (a) (b) 5 309024100% (c) 316301202293.4% 董事會報告 獨立核數師報告 75158 獨立核數師報告 19 19 • • • • 33,543,0008,487,000 — — —12345 22 35,340,0009% 35 4,492,000 ———— 獨立核數師報告 • • • • • • 獨立核數師報告 P04659 綜合損益及其他全面收益表 綜合財務狀況表 綜合權益變動表 綜合現金流量表 綜合財務報表附註 1. 40 2. (a)— 2. (b) 1 5(2020)—1123 1211028 1—5(2020)— 5(2020)15(2020)1 2. (b) 1— 21— 21 1028— 3. (a) (b) (c)— — — 3. (c)— —119.93(a)26—2 4. (a) 4. (b) 4. (c) (i)(ii) (i) (ii) (iii) (iv) 4(b) 16 4. (c) (i) (ii) (iii) (d) (e) (i) 10151010 4. (e) (ii)— •••••• 4. (f) 15 4. (f) (g) 15 4. (g) (i) •• 12 4. (g) (i) ••••• 90 4. (g) (i) 90 •••• 4. (g) (i) • • • • 4. (g) (ii) (h) 4. (i) (j) 4. (k) (l) • • • 4. (l) (i) (ii) (m) 9 4(g)(i) 4. (n) 12 (o) 4. (p) 4. (p) 12 (q) 4. (q) (r) (i) (ii) 4. (s) (a)(i)(ii)(iii)(b)(i)(ii)(iii)(iv)(v)(vi)(a)(vii)(a)(i)(viii) 5. 4 33,543,00017,487,0008,487,00014,413,000 5. 5,720,0006,632,000822,000861,000 35(b) 12 5. 1111 6. 9090 15 (a)—(b)—(c)— 6. (a) 6. 4 6. (b) • • 6. 6. (c) 6. (c) 6. (d) (e) 6. (e) 10%A70,44751,697B49,30143,009 7. 8. 9. 24138542338783376 11. —3,7983,949—1,9121,2755,7105,2242,331–30—(3,017)(449)5,0244,775